New Cancer Immunotherapy Index Posts 23% Gains Lead by Mentor

Capital, Inc. and Oncothyreon 

(For Immediate Release, August 28, 2009)  

SAN DIEGO,  The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks

increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a

peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR).  On July 10, 2009, 

Mentor Capital announced it had acquired a significant interest in and was a new public market proxy for Quantum Immunologics, Inc., a private company in FDA breast cancer trials.  Oncothyreon

(NASDAQ:ONTY), with significant lung cancer involvement, followed in CI Index performance with

a 71% gain in its stock.  Dendreon (NASDAQ:DNDN), with $2.7 Billion market capitalization, is the

largest company in the Cancer Immunotherapy Index, and experienced a 1,000% share price gain

during the Spring of 2009.

In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body’s own immune system is triggered to attack cancer cells. Patients report only flu-like symptoms as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers.    The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 Billion. The current combined market cap of the index component companies is $3.4 Billion. In addition to Mentor Capital, Oncothyreon and Dendreon, the CI Index features ImmunoCellular Theraputics (IMUC.OB), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics

(NASDAQ:CLDX), Northwest Biotherapeutics (NWBO.OB), CEL – SCI Corp. (AMEX:CVM) and

Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic

subsidiary, Antigen Express.

The CI Index was developed in consultation with  Mike Havrilla, PhD, co-founder and  Managing

Editor of BioMed Reports. Dr. Havrilla  actively manages 23 indexes.  The Cancer Immunotherapy

Index is primarily an immunotherapy  subset of his Cancer Diagnostic & Therapeutic

(Dx/Tx) Micro-Cap Index. Weekly detail updates of the Cancer Immunotherapy Index may be

reviewed at  www.MentorCapital.com.     

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference

from the MNTR Company Web Site above.  

For further information contact: 

Chet Billingsley, CEO                    P.O. Box 1709

Mentor Capital, Inc.                       Ramona, CA                  (760) 788 - 4700